| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Neolancerin targets the NF-κB signaling pathway and induces apoptosis in cancer cells. It reduces the viability of HL-60 human promyelocytic leukemia cells through mechanisms involving apoptosis induction. Its anti-inflammatory activity is attributed to the modulation of key molecular pathways. Its antimicrobial effects suggest additional targets in microbial cells.
|
|---|---|
| ln Vitro |
Neolancerin, with an IC50 value of 86.63 μM, dramatically lowers the viability of human promyelocytic leukemia cells (HL-60)[1].
In vitro, Neolancerin significantly reduces the viability of HL-60 human promyelocytic leukemia cells with an IC₅₀ of 86.63 μM. It has demonstrated anti-inflammatory and antimicrobial effects. The compound's cytotoxic activity is likely mediated through inhibition of NF-κB signaling and induction of apoptosis. These in vitro activities support its potential for cancer and inflammation research. |
| ln Vivo |
Specific in vivo activity data for Neolancerin are not available in the consulted sources. As a natural product with anti-inflammatory and cytotoxic effects, it may have potential in vivo efficacy in models of cancer and inflammation. However, no systematic in vivo studies have been reported.
|
| Enzyme Assay |
Typical in vitro assays for Neolancerin include cytotoxicity assays using HL-60 leukemia cells. Cells are cultured in 96-well plates and treated with the compound at various concentrations for 48-72 hours. Cell viability is assessed by MTT or similar assays, and IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for Neolancerin typically involve treating HL-60 leukemia cells with the compound at concentrations ranging from 1-100 µM. Cell viability is assessed by MTT assay. Apoptosis is evaluated by assessment of NF-κB signaling and other apoptotic markers.
|
| Animal Protocol |
In vivo animal experiments for Neolancerin have not been reported in the available literature. For potential anticancer or anti-inflammatory studies, typical animal models such as xenograft or inflammation models could be employed, but no specific protocols have been established for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Neolancerin are not available in the consulted sources. As a xanthone with a molecular weight of 406.34 g/mol, it would be expected to have moderate oral bioavailability. However, detailed ADME parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
No toxicological data are available for Neolancerin in the consulted sources. As a natural product, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
There have been reports that gentian (Gentiana thunbergii) and hypericum (Hypericum sampsonii) contain neocyanobacterium, and relevant data are available for reference.
Neolancerin is a natural xanthone (or sesquiterpene lactone) isolated from Hypericum perforatum and other plants. It exhibits anti-inflammatory, antimicrobial, and cytotoxic effects against HL-60 leukemia cells (IC₅₀ 86.63 μM) through NF-κB inhibition and apoptosis induction. It is a research compound for studying cancer, inflammation, and infectious diseases. It is not approved for any clinical indication. |
| Molecular Formula |
C19H18O10
|
|---|---|
| Molecular Weight |
568.48082
|
| Exact Mass |
406.089
|
| CAS # |
117221-65-5
|
| PubChem CID |
92029590
|
| Appearance |
Light yellow to yellow solid
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
29
|
| Complexity |
616
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC2=C(C=C1O)C(=O)C3=C(O2)C=C(C(=C3O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
KRCBALDMBZQTIQ-ZJKJAXBQSA-N
|
| InChi Code |
InChI=1S/C19H18O10/c20-5-11-15(24)17(26)18(27)19(29-11)12-8(22)4-10-13(16(12)25)14(23)7-3-6(21)1-2-9(7)28-10/h1-4,11,15,17-22,24-27H,5H2/t11-,15-,17+,18-,19+/m1/s1
|
| Chemical Name |
1,3,7-trihydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (246.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7591 mL | 8.7954 mL | 17.5908 mL | |
| 5 mM | 0.3518 mL | 1.7591 mL | 3.5182 mL | |
| 10 mM | 0.1759 mL | 0.8795 mL | 1.7591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
